CHM 10.0% 2.2¢ chimeric therapeutics limited

Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial, page-24

  1. 764 Posts.
    lightbulb Created with Sketch. 525
    I agree.

    This was published last night in Nature Cancer, "Targeting the innate immune system in pediatric and adult AML."

    https://www.nature.com/articles/s41375-024-02217-7


    I've rewatched this presentation several times but its making a lot of sense.

    https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02710995-69UCCL0B3668NS2PSD1Q0C53O2/pdf?access_token=0007rInP8VKAEnFJfs0cXGTQyMga
 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
(20min delay)
Last
2.2¢
Change
0.002(10.0%)
Mkt cap ! $18.39M
Open High Low Value Volume
2.2¢ 2.2¢ 2.0¢ $21.40K 1.025M

Buyers (Bids)

No. Vol. Price($)
5 385342 2.0¢
 

Sellers (Offers)

Price($) Vol. No.
2.2¢ 255138 3
View Market Depth
Last trade - 14.29pm 24/07/2024 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.